TP53 and neoplasm: Combination of the WEE1 inhibitor MK-1775 and the chemotherapy agent doxorubicin significantly reduced tumor growth in models of both NF1-associated and TP53-mutant MPNSTs, as well as in a sporadic MPNST model.